SANTA CLARA, Calif., Dec. 14, 2010 /PRNewswire/ — Cell
Biosciences, Inc. today announced the issuance of Patent No.
7,846,676 for “Methods and Devices for Analyte Detection” by the
United States Patent and Trademark Office.
The patent represents a key element of intellectual property
related to NanoPro assay technology. It is one of several within a
family directed towards the detection of specific proteins in
complex biological samples. NanoPro assay technology is used by
premier researchers in the fields of cancer research, stem cell
biology, diabetes and drug development to characterize proteins in
extremely small and precious samples, enabling accelerated
development of new therapeutics and identification of new
prognostic and diagnostic disease biomarkers.
“The NanoPro platform represents a transformational approach to
protein characterization,” commented Bob Gavin, Vice President of
Product Development at Cell Biosciences. “The platform’s ability to
study proteins in extremely small samples has led to its adoption
by leading research institutions and drug development companies
worldwide. We look forward to continuing the delivery of innovative
products based on this technology.”
About Cell Biosciences
Our company develops instrumentation systems, software and assay
products that drive discoveries in fields ranging from fundamental
protein research to biomarker discovery and personalized medicine.
With an installed base of over 10,000 systems, our customers
include leading research institutions and
pharmaceutical/biotechnology companies worldwide. Cell Biosciences
is headquartered in Santa Clara, California, with direct sales and
service in North America, Europe and Asia. For more
information, visit www.cellbiosciences.com.